ResMed Inc. (NYSE:RMD) has been a hot topic recently with various developments. This includes the company's decision to
acquire VirtuOx, a move touted to expand their reach in the market. ResMed's Q3 earnings have also surpassed estimates, their revenues showing particular strength. However, with one insider reducing their stake by 72%, some investors may be concerned. On a positive note, ResMed has announced their plans to maintain a consistent quarterly dividend of US$0.53. They have also seen strong Q3 earnings growth and are set to announce further financial performance results in upcoming calls. With recent earnings exceeding expectations and impressive profit jumps being reported, these developments have caught the attention of investment analysts.
Morgan Stanley has initiated ResMed with an overweight rating, indicating expected over-performance against the market. Amidst all this, ResMed has introduced
NightOwl to simplify home sleep apnea testing in the US, further showing their innovative capabilities in the market. Despite recent successes, it should be noted that the CEO of ResMed sold $1.68 million in stock, and other insiders also sold significant amounts.
Resmed RMD News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Sat, 03 May 2025 13:44:37 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -5
